APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anthracycline APIs

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. In commercial API terms, the category mainly covers doxorubicin, daunorubicin, epirubicin, idarubicin, and, in some markets, pirarubicin. These compounds share the anthracycline core architecture: a tetracyclic anthraquinone-type aglycone linked through a glycosidic bond to an amino sugar, typically daunosamine. They are commonly supplied as hydrochloride salts, including doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin hydrochloride, and idarubicin hydrochloride, because the finished products are predominantly parenteral cytotoxic formulations. Their pharmacological activity is driven by DNA intercalation and topoisomerase II inhibition, with consequent inhibition of nucleic acid synthesis and tumor-cell death.

Anthracycline APIs belong to the classical fermentation-based antitumor antibiotic segment of the pharmaceutical industry. Industrial production starts with microbial biosynthesis using Streptomyces strains, followed by extraction from the fermentation broth, multistep purification, salt formation, and tight control of related substances and potency. Doxorubicin is officially described in FDA labeling as an anthracycline topoisomerase inhibitor isolated from cultures of Streptomyces peucetius var. caesius, while daunorubicin is likewise a fermentation-derived anthracycline. Commercial derivatives are then obtained through downstream chemical transformation where needed; epirubicin, for example, is officially described as the 4-epimer of doxorubicin and a semi-synthetic derivative, and patent literature describes industrial epirubicin preparation from daunorubicin or epidaunorubicin intermediates. In practice, this makes anthracycline API manufacturing a hybrid platform combining fermentation, high-purity isolation, semisynthetic conversion, crystallization, and stringent GMP control suitable for injectable oncology use.

Therapeutically, anthracycline APIs support a broad oncology indication set spanning both hematologic malignancies and solid tumors. Daunorubicin and idarubicin are established leukemia anthracyclines, especially in acute myeloid leukemia and, depending on product labeling, acute lymphoblastic leukemia. Doxorubicin has one of the broadest label footprints in the class, covering breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, acute leukemias, soft tissue sarcoma, bone sarcoma, Wilms tumor, and neuroblastoma, while epirubicin is a core breast-cancer anthracycline in adjuvant therapy. Across the class, clinical utility is balanced by well-defined dose-limiting toxicities, particularly myelosuppression and cumulative cardiotoxicity, which is why anthracycline APIs are handled as highly controlled cytotoxic drug substances throughout development, manufacture, and clinical use.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Anthracycline APIs, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable anthracycline apis performance?

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Industry Research

Anthracycline APIs Industry Research Report 2026

3 August 2026123 pages

Choose your research edition.

Industry ResearchAnthracycline APIs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthracycline APIs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Anthracycline APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthracycline APIs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthracycline APIs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. In commercial API terms, the category mainly covers doxorubicin, daunorubicin, epirubicin, idarubicin, and, in some markets, pirarubicin. These compounds share the anthracycline core architecture: a tetracyclic anthraquinone-type aglycone linked through a glycosidic bond to an amino sugar, typically daunosamine. They are commonly supplied as hydrochloride salts, including doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin hydrochloride, and idarubicin hydrochloride, because the finished products are predominantly parenteral cytotoxic formulations. Their pharmacological activity is driven by DNA intercalation and topoisomerase II inhibition, with consequent inhibition of nucleic acid synthesis and tumor-cell death.

Anthracycline APIs belong to the classical fermentation-based antitumor antibiotic segment of the pharmaceutical industry. Industrial production starts with microbial biosynthesis using Streptomyces strains, followed by extraction from the fermentation broth, multistep purification, salt formation, and tight control of related substances and potency. Doxorubicin is officially described in FDA labeling as an anthracycline topoisomerase inhibitor isolated from cultures of Streptomyces peucetius var. caesius, while daunorubicin is likewise a fermentation-derived anthracycline. Commercial derivatives are then obtained through downstream chemical transformation where needed; epirubicin, for example, is officially described as the 4-epimer of doxorubicin and a semi-synthetic derivative, and patent literature describes industrial epirubicin preparation from daunorubicin or epidaunorubicin intermediates. In practice, this makes anthracycline API manufacturing a hybrid platform combining fermentation, high-purity isolation, semisynthetic conversion, crystallization, and stringent GMP control suitable for injectable oncology use.

Therapeutically, anthracycline APIs support a broad oncology indication set spanning both hematologic malignancies and solid tumors. Daunorubicin and idarubicin are established leukemia anthracyclines, especially in acute myeloid leukemia and, depending on product labeling, acute lymphoblastic leukemia. Doxorubicin has one of the broadest label footprints in the class, covering breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, acute leukemias, soft tissue sarcoma, bone sarcoma, Wilms tumor, and neuroblastoma, while epirubicin is a core breast-cancer anthracycline in adjuvant therapy. Across the class, clinical utility is balanced by well-defined dose-limiting toxicities, particularly myelosuppression and cumulative cardiotoxicity, which is why anthracycline APIs are handled as highly controlled cytotoxic drug substances throughout development, manufacture, and clinical use.

Read the full market overview

The global Anthracycline APIs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Anthracycline APIs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Anthracycline APIs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Anthracycline APIs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Anthracycline APIs include Synbias-Gemini, Intas Pharma, MicroBiopharm Japan, TAPI, Humble Healthcaare, Sterling Biotech, Olon S.p.A., Lunan Pharmaceutical and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Anthracycline APIs market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Anthracycline APIs Market by Company

Synbias-Gemini

Intas Pharma

MicroBiopharm Japan

TAPI

Humble Healthcaare

Sterling Biotech

Olon S.p.A.

Lunan Pharmaceutical

DZD (Heze) Pharmaceutical

Zhejiang Hisun

Meiji Seika Pharma

Anthracycline APIs Segment by Type

Doxorubicin API

Daunorubicin API

Epirubicin API

Idarubicin API

Pirarubicin API

Other

Anthracycline APIs Segment by Application

Solid Tumors

Hematologic Malignancies

Others

Anthracycline APIs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthracycline APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthracycline APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthracycline APIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Anthracycline APIs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Anthracycline APIs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Anthracycline APIs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Anthracycline APIs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Anthracycline APIs Sales (kg) of Manufacturers (2021-2026) Table 7. Global Anthracycline APIs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Anthracycline APIs Revenue of Manufacturers (2021-2026) Table 9. Global Anthracycline APIs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Anthracycline APIs Average Price (USD/g) of Manufacturers (2021-2026) Table 11. Global Anthracycline APIs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Anthracycline APIs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Anthracycline APIs, Product Type & Application Table 14. Global Anthracycline APIs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Anthracycline APIs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Synbias-Gemini Company Information Table 19. Synbias-Gemini Business Overview Table 20. Synbias-Gemini Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 21. Synbias-Gemini Anthracycline APIs Product Portfolio Table 22. Synbias-Gemini Recent Developments Table 23. Intas Pharma Company Information Table 24. Intas Pharma Business Overview Table 25. Intas Pharma Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 26. Intas Pharma Anthracycline APIs Product Portfolio Table 27. Intas Pharma Recent Developments Table 28. MicroBiopharm Japan Company Information Table 29. MicroBiopharm Japan Business Overview Table 30. MicroBiopharm Japan Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 31. MicroBiopharm Japan Anthracycline APIs Product Portfolio Table 32. MicroBiopharm Japan Recent Developments Table 33. TAPI Company Information Table 34. TAPI Business Overview Table 35. TAPI Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 36. TAPI Anthracycline APIs Product Portfolio Table 37. TAPI Recent Developments Table 38. Humble Healthcaare Company Information Table 39. Humble Healthcaare Business Overview Table 40. Humble Healthcaare Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 41. Humble Healthcaare Anthracycline APIs Product Portfolio Table 42. Humble Healthcaare Recent Developments Table 43. Sterling Biotech Company Information Table 44. Sterling Biotech Business Overview Table 45. Sterling Biotech Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 46. Sterling Biotech Anthracycline APIs Product Portfolio Table 47. Sterling Biotech Recent Developments Table 48. Olon S.p.A. Company Information Table 49. Olon S.p.A. Business Overview Table 50. Olon S.p.A. Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 51. Olon S.p.A. Anthracycline APIs Product Portfolio Table 52. Olon S.p.A. Recent Developments Table 53. Lunan Pharmaceutical Company Information Table 54. Lunan Pharmaceutical Business Overview Table 55. Lunan Pharmaceutical Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 56. Lunan Pharmaceutical Anthracycline APIs Product Portfolio Table 57. Lunan Pharmaceutical Recent Developments Table 58. DZD (Heze) Pharmaceutical Company Information Table 59. DZD (Heze) Pharmaceutical Business Overview Table 60. DZD (Heze) Pharmaceutical Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 61. DZD (Heze) Pharmaceutical Anthracycline APIs Product Portfolio Table 62. DZD (Heze) Pharmaceutical Recent Developments Table 63. Zhejiang Hisun Company Information Table 64. Zhejiang Hisun Business Overview Table 65. Zhejiang Hisun Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 66. Zhejiang Hisun Anthracycline APIs Product Portfolio Table 67. Zhejiang Hisun Recent Developments Table 68. Meiji Seika Pharma Company Information Table 69. Meiji Seika Pharma Business Overview Table 70. Meiji Seika Pharma Anthracycline APIs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 71. Meiji Seika Pharma Anthracycline APIs Product Portfolio Table 72. Meiji Seika Pharma Recent Developments Table 73. Global Anthracycline APIs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Anthracycline APIs Sales by Region (2021-2026) & (kg) Table 75. Global Anthracycline APIs Sales Market Share by Region (2021-2026) Table 76. Global Anthracycline APIs Sales by Region (2027-2032) & (kg) Table 77. Global Anthracycline APIs Sales Market Share by Region (2027-2032) Table 78. Global Anthracycline APIs Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Anthracycline APIs Revenue Market Share by Region (2021-2026) Table 80. Global Anthracycline APIs Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Anthracycline APIs Revenue Market Share by Region (2027-2032) Table 82. North America Anthracycline APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 84. North America Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 85. North America Anthracycline APIs Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Anthracycline APIs Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Anthracycline APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 89. Europe Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 90. Europe Anthracycline APIs Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Anthracycline APIs Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Anthracycline APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 94. Asia Pacific Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 95. Asia Pacific Anthracycline APIs Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Anthracycline APIs Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Anthracycline APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 99. South America Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 100. South America Anthracycline APIs Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Anthracycline APIs Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Anthracycline APIs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 104. Middle East and Africa Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 105. Middle East and Africa Anthracycline APIs Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Anthracycline APIs Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Anthracycline APIs Sales by Type (2021-2026) & (kg) Table 108. Global Anthracycline APIs Sales by Type (2027-2032) & (kg) Table 109. Global Anthracycline APIs Sales Market Share by Type (2021-2026) Table 110. Global Anthracycline APIs Sales Market Share by Type (2027-2032) Table 111. Global Anthracycline APIs Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Anthracycline APIs Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Anthracycline APIs Revenue Market Share by Type (2021-2026) Table 114. Global Anthracycline APIs Revenue Market Share by Type (2027-2032) Table 115. Global Anthracycline APIs Price by Type (2021-2026) & (USD/g) Table 116. Global Anthracycline APIs Price by Type (2027-2032) & (USD/g) Table 117. Global Anthracycline APIs Sales by Application (2021-2026) & (kg) Table 118. Global Anthracycline APIs Sales by Application (2027-2032) & (kg) Table 119. Global Anthracycline APIs Sales Market Share by Application (2021-2026) Table 120. Global Anthracycline APIs Sales Market Share by Application (2027-2032) Table 121. Global Anthracycline APIs Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Anthracycline APIs Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Anthracycline APIs Revenue Market Share by Application (2021-2026) Table 124. Global Anthracycline APIs Revenue Market Share by Application (2027-2032) Table 125. Global Anthracycline APIs Price by Application (2021-2026) & (USD/g) Table 126. Global Anthracycline APIs Price by Application (2027-2032) & (USD/g) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Anthracycline APIs Distributors List Table 130. Anthracycline APIs Customers List Table 131. Anthracycline APIs Industry Trends Table 132. Anthracycline APIs Industry Drivers Table 133. Anthracycline APIs Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Anthracycline APIs Product Image Figure 5. Global Anthracycline APIs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Anthracycline APIs Market Size (2021-2032) & (US$ Million) Figure 7. Global Anthracycline APIs Sales (2021-2032) & (kg) Figure 8. Global Anthracycline APIs Average Price (USD/g) & (2021-2032) Figure 9. Doxorubicin API Product Image Figure 10. Daunorubicin API Product Image Figure 11. Epirubicin API Product Image Figure 12. Idarubicin API Product Image Figure 13. Pirarubicin API Product Image Figure 14. Other Product Image Figure 15. Solid Tumors Product Image Figure 16. Hematologic Malignancies Product Image Figure 17. Others Product Image Figure 18. Global Anthracycline APIs Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Anthracycline APIs, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Anthracycline APIs Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Anthracycline APIs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Anthracycline APIs Sales by Region in 2025 Figure 24. Global Anthracycline APIs Revenue by Region in 2025 Figure 25. North America Anthracycline APIs Market Size by Country in 2025 Figure 26. North America Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 27. North America Anthracycline APIs Revenue Market Share by Country (2021-2032) Figure 28. United States Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Anthracycline APIs Market Size by Country in 2025 Figure 32. Europe Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 33. Europe Anthracycline APIs Revenue Market Share by Country (2021-2032) Figure 34. Germany Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Anthracycline APIs Market Size by Country in 2025 Figure 45. Asia Pacific Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Anthracycline APIs Revenue Market Share by Country (2021-2032) Figure 47. China Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Anthracycline APIs Market Size by Country in 2025 Figure 56. South America Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 57. South America Anthracycline APIs Revenue Market Share by Country (2021-2032) Figure 58. Brazil Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Colombia Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Anthracycline APIs Market Size by Country in 2025 Figure 63. Middle East and Africa Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Anthracycline APIs Revenue Market Share by Country (2021-2032) Figure 65. Egypt Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Anthracycline APIs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Anthracycline APIs Sales Market Share by Type (2021-2032) Figure 71. Global Anthracycline APIs Revenue Market Share by Type (2021-2032) Figure 72. Global Anthracycline APIs Price (USD/g) by Type (2021-2032) Figure 73. Global Anthracycline APIs Sales Market Share by Application (2021-2032) Figure 74. Global Anthracycline APIs Revenue Market Share by Application (2021-2032) Figure 75. Global Anthracycline APIs Price (USD/g) by Application (2021-2032) Figure 76. Anthracycline APIs Value Chain Figure 77. Anthracycline APIs Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Anthracycline APIs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Doxorubicin API
  • Daunorubicin API
  • Epirubicin API
  • Idarubicin API
  • Pirarubicin API
  • Other
Applications
  • Solid Tumors
  • Hematologic Malignancies
  • Others
Companies covered
  • Synbias-Gemini
  • Intas Pharma
  • MicroBiopharm Japan
  • TAPI
  • Humble Healthcaare
  • Sterling Biotech
  • Olon S.p.A.
  • Lunan Pharmaceutical
  • DZD (Heze) Pharmaceutical
  • Zhejiang Hisun
  • Meiji Seika Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Anthracycline APIs Market Size (2021-2032)
  4. 2.2.2 Global Anthracycline APIs Sales (2021-2032)
  5. 2.2.3 Global Anthracycline APIs Market Average Price (2021-2032)
  6. 2.3 Anthracycline APIs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Doxorubicin API
  9. 2.3.3 Daunorubicin API
  10. 2.3.4 Epirubicin API
  11. 2.3.5 Idarubicin API
  12. 2.3.6 Pirarubicin API
  13. 2.3.7 Other
  14. 2.4 Anthracycline APIs by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Solid Tumors
  17. 2.4.3 Hematologic Malignancies
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Anthracycline APIs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Anthracycline APIs Sales (kg) of Manufacturers (2021-2026)
  3. 3.3 Global Anthracycline APIs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Anthracycline APIs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Anthracycline APIs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Anthracycline APIs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Anthracycline APIs, Product Type & Application
  8. 3.8 Global Manufacturers of Anthracycline APIs, Established Date
  9. 3.9 Global Anthracycline APIs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Synbias-Gemini
  2. 4.1.1 Synbias-Gemini Company Information
  3. 4.1.2 Synbias-Gemini Business Overview
  4. 4.1.3 Synbias-Gemini Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Synbias-Gemini Anthracycline APIs Product Portfolio
  6. 4.1.5 Synbias-Gemini Recent Developments
  7. 4.2 Intas Pharma
  8. 4.2.1 Intas Pharma Company Information
  9. 4.2.2 Intas Pharma Business Overview
  10. 4.2.3 Intas Pharma Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Intas Pharma Anthracycline APIs Product Portfolio
  12. 4.2.5 Intas Pharma Recent Developments
  13. 4.3 MicroBiopharm Japan
  14. 4.3.1 MicroBiopharm Japan Company Information
  15. 4.3.2 MicroBiopharm Japan Business Overview
  16. 4.3.3 MicroBiopharm Japan Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 MicroBiopharm Japan Anthracycline APIs Product Portfolio
  18. 4.3.5 MicroBiopharm Japan Recent Developments
  19. 4.4 TAPI
  20. 4.4.1 TAPI Company Information
  21. 4.4.2 TAPI Business Overview
  22. 4.4.3 TAPI Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 TAPI Anthracycline APIs Product Portfolio
  24. 4.4.5 TAPI Recent Developments
  25. 4.5 Humble Healthcaare
  26. 4.5.1 Humble Healthcaare Company Information
  27. 4.5.2 Humble Healthcaare Business Overview
  28. 4.5.3 Humble Healthcaare Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Humble Healthcaare Anthracycline APIs Product Portfolio
  30. 4.5.5 Humble Healthcaare Recent Developments
  31. 4.6 Sterling Biotech
  32. 4.6.1 Sterling Biotech Company Information
  33. 4.6.2 Sterling Biotech Business Overview
  34. 4.6.3 Sterling Biotech Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sterling Biotech Anthracycline APIs Product Portfolio
  36. 4.6.5 Sterling Biotech Recent Developments
  37. 4.7 Olon S.p.A.
  38. 4.7.1 Olon S.p.A. Company Information
  39. 4.7.2 Olon S.p.A. Business Overview
  40. 4.7.3 Olon S.p.A. Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Olon S.p.A. Anthracycline APIs Product Portfolio
  42. 4.7.5 Olon S.p.A. Recent Developments
  43. 4.8 Lunan Pharmaceutical
  44. 4.8.1 Lunan Pharmaceutical Company Information
  45. 4.8.2 Lunan Pharmaceutical Business Overview
  46. 4.8.3 Lunan Pharmaceutical Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Lunan Pharmaceutical Anthracycline APIs Product Portfolio
  48. 4.8.5 Lunan Pharmaceutical Recent Developments
  49. 4.9 DZD (Heze) Pharmaceutical
  50. 4.9.1 DZD (Heze) Pharmaceutical Company Information
  51. 4.9.2 DZD (Heze) Pharmaceutical Business Overview
  52. 4.9.3 DZD (Heze) Pharmaceutical Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 DZD (Heze) Pharmaceutical Anthracycline APIs Product Portfolio
  54. 4.9.5 DZD (Heze) Pharmaceutical Recent Developments
  55. 4.10 Zhejiang Hisun
  56. 4.10.1 Zhejiang Hisun Company Information
  57. 4.10.2 Zhejiang Hisun Business Overview
  58. 4.10.3 Zhejiang Hisun Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Zhejiang Hisun Anthracycline APIs Product Portfolio
  60. 4.10.5 Zhejiang Hisun Recent Developments
  61. 4.11 Meiji Seika Pharma
  62. 4.11.1 Meiji Seika Pharma Company Information
  63. 4.11.2 Meiji Seika Pharma Business Overview
  64. 4.11.3 Meiji Seika Pharma Anthracycline APIs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Meiji Seika Pharma Anthracycline APIs Product Portfolio
  66. 4.11.5 Meiji Seika Pharma Recent Developments
5 Global Anthracycline APIs Market Scenario by Region
  1. 5.1 Global Anthracycline APIs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Anthracycline APIs Sales by Region: 2021-2032
  3. 5.2.1 Global Anthracycline APIs Sales by Region: 2021-2026
  4. 5.2.2 Global Anthracycline APIs Sales by Region: 2027-2032
  5. 5.3 Global Anthracycline APIs Revenue by Region: 2021-2032
  6. 5.3.1 Global Anthracycline APIs Revenue by Region: 2021-2026
  7. 5.3.2 Global Anthracycline APIs Revenue by Region: 2027-2032
  8. 5.4 North America Anthracycline APIs Market Facts & Figures by Country
  9. 5.4.1 North America Anthracycline APIs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Anthracycline APIs Sales by Country (2021-2032)
  11. 5.4.3 North America Anthracycline APIs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Anthracycline APIs Market Facts & Figures by Country
  16. 5.5.1 Europe Anthracycline APIs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Anthracycline APIs Sales by Country (2021-2032)
  18. 5.5.3 Europe Anthracycline APIs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Anthracycline APIs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Anthracycline APIs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Anthracycline APIs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Anthracycline APIs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Anthracycline APIs Market Facts & Figures by Country
  41. 5.7.1 South America Anthracycline APIs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Anthracycline APIs Sales by Country (2021-2032)
  43. 5.7.3 South America Anthracycline APIs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Anthracycline APIs Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Anthracycline APIs Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Anthracycline APIs Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Anthracycline APIs Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Anthracycline APIs Sales by Type (2021-2032)
  2. 6.1.1 Global Anthracycline APIs Sales by Type (2021-2032) & (kg)
  3. 6.1.2 Global Anthracycline APIs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Anthracycline APIs Revenue by Type (2021-2032)
  5. 6.2.1 Global Anthracycline APIs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Anthracycline APIs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Anthracycline APIs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Anthracycline APIs Sales by Application (2021-2032)
  2. 7.1.1 Global Anthracycline APIs Sales by Application (2021-2032) & (kg)
  3. 7.1.2 Global Anthracycline APIs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Anthracycline APIs Revenue by Application (2021-2032)
  5. 7.2.1 Global Anthracycline APIs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Anthracycline APIs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Anthracycline APIs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Anthracycline APIs Value Chain Analysis
  2. 8.1.1 Anthracycline APIs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Anthracycline APIs Production Mode & Process
  5. 8.2 Anthracycline APIs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Anthracycline APIs Distributors
  8. 8.2.3 Anthracycline APIs Customers
9 Global Anthracycline APIs Analyzing Market Dynamics
  1. 9.1 Anthracycline APIs Industry Trends
  2. 9.2 Anthracycline APIs Industry Drivers
  3. 9.3 Anthracycline APIs Industry Opportunities and Challenges
  4. 9.4 Anthracycline APIs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst